-
公开(公告)号：EP2958942B1
公开(公告)日：2020-06-03
申请号：EP14711341.9
申请日：2014-02-20
发明人： BROGDON, Jennifer , GILL, Saar , JUNE, Carl, H. , KALOS, Michael, D. , LOEW, Andreas , SCHOLLER, John
IPC分类号： C07K16/28 , C07K14/725 , C07K14/705 , A61K39/00 , A61K38/17
-
公开(公告)号：EP3174546B1
公开(公告)日：2019-10-30
申请号：EP15753252.4
申请日：2015-07-31
IPC分类号： C07K16/28 , A61K39/00 , A61K35/17 , C07K14/705 , A61K39/395 , A61K31/436 , C07K14/725 , C12N5/0783
-
公开(公告)号：EP4275699A2
公开(公告)日：2023-11-15
申请号：EP23193203.9
申请日：2013-02-22
发明人： JUNE, Carl H. , SCHOLLER, John , POSEY, Avery D.
IPC分类号： A61K39/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
-
公开(公告)号：EP2970482B1
公开(公告)日：2019-03-06
申请号：EP14722469.5
申请日：2014-03-15
IPC分类号： C07K16/28 , A61K35/14 , C07K14/725 , C07K14/705 , C07K16/30 , C12N5/0783 , A61P35/00
-
5.发明公开TREATMENT OF CANCER USING HUMANIZED ANTI-EGFRVIII CHIMERIC ANTIGEN RECEPTOR 审中-公开百日咳ON BS BS IT IT IT TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR TOR
公开(公告)号：EP2958943A1
公开(公告)日：2015-12-30
申请号：EP14713280.7
申请日：2014-02-20
申请人： The Trustees of The University of Pennsylvania , University of Pittsburgh - Of the Commonwealth System of Higher Education , Novartis AG
发明人： BROGDON, Jennifer , LOEW, Andreas , JOHNSON, Laura Alexandra , JUNE, Carl H. , MAUS, Marcela , SCHOLLER, John , OKADA, Hideho
CPC分类号： C07K16/2863 , A61K35/17 , A61K38/00 , A61K2039/505 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
摘要翻译： 本发明提供用于治疗与EGFRvIII表达相关的疾病的组合物和方法。 本发明还涉及对EGFRvIII特异性的嵌合抗原受体（CAR），编码它的载体和包含抗-EGFRVIII CAR的重组T细胞。 本发明还包括施用表达CAR的遗传修饰的T细胞的方法，其包含抗EGFRvIII结合结构域。
-
公开(公告)号：EP4067382A1
公开(公告)日：2022-10-05
申请号：EP22159001.1
申请日：2014-03-15
IPC分类号： C07K16/28 , A61K35/14 , C07K14/725 , C07K14/705 , C07K16/30 , C12N5/0783 , A61P35/00
摘要： The disclosure provides compositions and methods for treating diseases associated with expression of CD19. The disclosure also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The disclosure also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD 19 binding domain.
-
-
8.发明公开USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS 审中-公开VERWENDUNG DER CD2-SIGNALISIERUNGSDOMÄNEBEICHIMÄREN抗生素DER ZWEITEN GENERATION
公开(公告)号：EP2817331A1
公开(公告)日：2014-12-31
申请号：EP13751899.9
申请日：2013-02-22
发明人： JUNE, Carl H. , SCHOLLER, John , POSEY, Avery, D.
IPC分类号： C07K14/705
CPC分类号： C07K14/7051 , C07K14/705 , C07K14/70507 , C07K16/2803 , C07K16/30 , C07K2319/00 , C07K2319/02 , C12N15/85
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
摘要翻译： 本发明提供了治疗人类癌症的组合物和方法。 本发明涉及施用表达具有抗原结合结构域的CAR的遗传修饰的T细胞，跨膜结构域，CD2信号结构域和CD3ζ信号结构域。 本发明还包括将CD2并入CAR中以改变CAR-T细胞在阴性和阳性方向的细胞因子产生。
-
公开(公告)号：EP4205749A1
公开(公告)日：2023-07-05
申请号：EP22210490.3
申请日：2015-07-31
IPC分类号： A61K35/17 , C07K14/705 , A61K31/436 , A61K39/00 , A61K39/395 , C07K14/725 , C07K16/28 , C12N5/0783
摘要： This disclosure provides, for instance subset-optimized CART cells and related methods. For instance, the disclosure describes methods and compositions of CD4 + and CD8 + T cells that express CARs containing specific combinations of intracellular signaling domains can be used to increase persistence and anti-tumor activity of the infused CAR-expressing T cells for treating a subject having a disease, e.g., a cancer.
-
公开(公告)号：EP3174546A1
公开(公告)日：2017-06-07
申请号：EP15753252.4
申请日：2015-07-31
IPC分类号： A61K35/17 , C07K14/705
摘要： This disclosure provides, for instance subset-optimized CART cells and related methods. For instance, the disclosure describes methods and compositions of CD4′ and CD8′ T cells that express CARs containing specific combinations of intracellular signaling domains can be used to increase persistence and anti-tumor activity of the infused CAR-expressing T cells for treating a subject having a disease, e.g., a cancer.
摘要翻译： 本公开提供了例如子集优化的CART单元和相关方法。 例如，本公开内容描述了表达CAR的CD4 +和CD8 + T细胞的方法和组合物，其中含有细胞内信号传导结构域的特定组合可用于增加注入的表达CAR的T细胞的持久性和抗肿瘤活性，用于治疗患有 疾病，例如癌症。
-
-
-
-
-
-
-
-
-
搜索结果
21 条记录 (耗时 0.022 秒)
